SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin trades in green on the bourses

29 Jun 2018 Evaluate

Lupin is currently trading at Rs. 900.05, up by 5.00 points or 0.56% from its previous closing of Rs. 895.05 on the BSE.

The scrip opened at Rs. 900.50 and has touched a high and low of Rs. 912.60 and Rs. 894.90 respectively. So far 113724 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1176.00 on 19-Jul-2017 and a 52 week low of Rs. 723.55 on 15-May-2018.

Last one week high and low of the scrip stood at Rs. 921.35 and Rs. 878.40 respectively. The current market cap of the company is Rs. 41131.18 crore.

The promoters holding in the company stood at 47.01%, while Institutions and Non-Institutions held 37.60% and 15.40% respectively.

Lupin and the Municipal Corporation of Greater Mumbai (MCGM) have united and launched a joint campaign to detect and address active cases of TB in Mumbai. The door-to-door Active Case Finding (ACF) campaign will cover all high-risk population areas selected from all 24 wards under the MCGM.

This campaign and the methodology of execution follows the success of ACF pilot that was conducted by Lupin along with the TB department of the MCGM in 2017. The new 12-month project will involve comprehensive end-to-end TB detection, treatment and follow-up with door-to-door visits conducted in high-risk areas to identify symptomatic patients.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2457.60 -32.25 (-1.30%)
08-Jul-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1887.95
Dr. Reddys Labs. 1351.00
Cipla 1435.00
Zydus Lifesciences 1149.00
Lupin 2457.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: